edoxaban

(redirected from Savaysa)
Also found in: Medical.
Related to Savaysa: edoxaban, Eliquis
Translations

edoxaban

n edoxabán m
References in periodicals archive ?
Most recently, he held commercial leadership roles in the launch of multiple specialty pharmaceutical products for the treatment of cardiovascular disease, including RANEXA, EFFIENT, and SAVAYSA.
NOACs such as Pradaxa, Eliquis, Xarelto and Savaysa provide physicians with numerous treatment options, which can be managed depending upon the patient's risk profile.
some markets and Savaysa in others (edoxaban) is an anticoagulant or a
5mg, 5mg Savaysa (edoxaban) 15mg, 30mg, 60mg Agent Class Mechanism PLATELET platelet aggregation and/or AGGREGATION platelet activation inhibitor that INHIBITORS blocks the aggregation of platelets; reduces blood viscosity ANTICOAGULANT inhibiting synthesis of vitamin K VITAMIN K dependent clotting factors which ANTAGONIST include factors 2, 7, 9 and 10, and the anticoagulant proteins C and S ANTICOAGULANT competitive, direct thrombin DIRECT THROMBIN inhibitors which prevent thrombus INHIBITOR development.
The multinational, randomized phase 3b study will evaluate a treatment regimen based on the companys oral, once-daily direct factor Xa-inhibitor edoxaban (known by the brand name LIXIANA outside the US and SAVAYSA in the US) against a vitamin K antagonist based regimen, with or without antiplatelet therapy, in patients with atrial fibrillation (AF) following successful transcatheter aortic valve implantation (TAVI).
M2 EQUITYBITES-November 4, 2014-US FDA's Cardiovascular and Renal Drugs Advisory Committee endorses use of Daiichi Sankyo's Savaysa
M2 PHARMA-November 4, 2014-US FDA's Cardiovascular and Renal Drugs Advisory Committee endorses use of Daiichi Sankyo's Savaysa
The availability of SAVAYSA provides appropriate patients and their physicians with a new anticoagulant that has been shown to reduce the risk of stroke and SE with significantly less major bleeding compared to warfarin in patients with NVAF and that treats venous thromboembolism with significantly less clinically relevant bleeding compared to warfarin, said Howard Rutman, M.
Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
Food and Drug Administration (FDA) has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).